Scientific Reports (Dec 2023)

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients

  • Anna Crispo,
  • Livia S. A. Augustin,
  • Assunta Luongo,
  • Claudia Calderaio,
  • Joao Breda,
  • Sergio Coluccia,
  • Alessandra Calabrese,
  • Vittorio Marrazzo,
  • Rosa Giannatiempo,
  • Paola Trasacco,
  • Elvira Palumbo,
  • Sara Vitale,
  • Giuseppe Porciello,
  • Piergiacomo Di Gennaro,
  • Roberta Caputo,
  • Giuseppe Buono,
  • Claudio Vernieri,
  • Francesco Schettini,
  • Maria Grimaldi,
  • Flavia Nocerino,
  • Egidio Celentano,
  • Alfonso Amore,
  • Mario Giuliano,
  • Pietro De Placido,
  • Carmine De Angelis,
  • Roberto Bianco,
  • Michelino De Laurentiis,
  • Carlo La Vecchia,
  • Grazia Arpino

DOI
https://doi.org/10.1038/s41598-023-45439-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Obesity and metabolic disorders have been associated with poor outcomes in non-Mediterranean breast cancer (BC) patients. The purpose of this study was to investigate the prognostic potential of anthropometric variables in patients with early BC living in Southern Mediterranean region of Italy. We enrolled 955 consecutive early BC patients treated in hospitals in Naples between 2009 and 2013 (median follow-up 11.8-year ending 15/09/2022). Body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR) and metabolic syndrome (MetS) were collected. All-cause and BC-specific mortality were calculated. At the last day of contact 208 (22%) patients had died, 131 (14%) from BC. High WC (≥ 88 cm) or WHR (> 0.85) and the MetS were significantly associated with moderately increased risk of all-cause mortality (HR=1.39, 1.62, 1.61, respectively). A significant increased risk of BC-specific mortality was found in obese patients, in those with high WC, high WHR and those with MetS (HR=1.72, 1.71, 1.80, 1.81, respectively). Central obesity significantly increased total and BC-specific mortality particularly in pre-menopausal women and in luminal subtypes, while in post-menopause MetS was a stronger risk factor. Obesity and MetS may impair the effectiveness of BC therapies hence active lifestyle interventions are encouraged.